Intraocular Chemotherapy for Vitreoretinal Lymphoma: a review

Thumbnail Image
Date
2019-11-03
Authors
Kvopka, Michael
Lake, Stewart
Smith, Justine R
Journal Title
Journal ISSN
Volume Title
Publisher
Wiley
Abstract
Vitreoretinal lymphomas are rare ocular cancers, and the subset of primary central nervous system lymphomas that are based in the posterior eye. These tumours are challenging to treat, and today management generally involves a multispecialty team coordinating a treatment protocol that may include intraocular chemotherapy, ocular irradiation, systemic chemotherapy and/or autologous stem cell transplantation. The ophthalmologist has specific responsibility for the intraocular chemotherapy, which is delivered to the eye by intravitreal injection. The most commonly injected drugs are methotrexate—an anti‐metabolite—and rituximab—an anti‐human B cell monoclonal antibody. A range of intraocular chemotherapy treatment schedules have been described in the medical literature, although to date there have been no randomized clinical trials of these schedules. In this article, we review the development and current status of intraocular chemotherapy for vitreoretinal lymphoma.
Description
© 2019 Royal Australian and New Zealand College of Ophthalmologists
Keywords
drug therapy, eye, lymphoma, retina, vitreoretinal lymphoma, intraocular chemotherapy
Citation
Kvopka, M., Lake, S. R., & Smith, J. R. (2019). Intraocular chemotherapy for vitreoretinal lymphoma: A review. Clinical & Experimental Ophthalmology. https://doi.org/10.1111/ceo.13668